|
|
|
| Resveratrol supplementation in the treatment of ulcerative colitis |
| Li Mingzhi, Liu Tiemei |
| Department of Endoscopy Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University Shanghai 201799 China |
|
|
|
|
Abstract Objective To investigate the clinical efficacy of resveratrol combined with mesalazine in the treatment of ulcerative
colitis and the effect on inflammatory factors. Method A total of 112 UC patients admitted to Qingpu Branch of Zhongshan Hospital
Affiliated to Fudan University from January 2018 to December 2020 were selected. Patients were divided into mesalamine treatment
group and mesalazine combined with resveratrol treatment group 56 patients each. Patients in both groups were treated for 8 weeks.
After treatment the efficacy of the two groups colonoscopy scores disease activity index quality of life anxiety and depression
status and serum tumor necrosis factor-α TNF-α interleukin-10 IL-10 C-reactive protein CRP and erythrocyte sedimentation
rate ESR before and after treatment were observed and compared. Result The overall effective rate of the combined treatment group
was 96. 42% 54 / 56 higher than that of the control group 83. 92% 47 / 56 P = 0. 028 . The modified Mayo score Baron
endoscopic score and DAI score in both groups were lower than those before treatment. The 3 scores in the combined treatment group
were lower than that of the control group with statistically significant difference P<0. 05 . After treatment the scores of IBDQ quality
of life anxiety and depression in both groups were better than those before treatment and the 3 scores in the combined treatment group
were lower than those of the control group P<0. 05 . After treatment the serum levels of TNF-α IL-10 CRP and ESR in both
groups were lower than those before treatment and the level of TNF-α IL-10 CRP and ESR of the combined treatment group were
significantly lower than those of the control group P< 0. 05 . Conclusion Resveratrol supplemental has a significant effect on the
clinical outcomes quality of life and systemic inflammation in patients with mild to moderate ulcerative colitis.
|
|
Received: 13 June 2022
|
|
|
|
|
|
|
